MedicalCV Establishes Scientific Advisory Board Comprised of Distinguished Cardiac Surgeons and Scientific Experts Dr. Patrick M. McCarthy, Chief of Cardiothoracic Surgery at Northwestern Memorial Hospital, Joins as Chairman of the Scientific Advisory Board MINNEAPOLIS, July 13 /PRNewswire-FirstCall/ -- MedicalCV, Inc. (OTC:MDCV) (BULLETIN BOARD: MDCV) , http://www.medcvinc.com/ , a cardiovascular surgery device manufacturer which utilizes a laser-based technology for cardiac tissue ablation and focuses on the surgical needs surrounding atrial fibrillation, announced today that it has established its Scientific Advisory Board of prominent cardiothoracic surgeons. MedicalCV is pleased to announce that Patrick M. McCarthy, MD, Chief of Cardiothoracic Surgery and Co-Director of the Bluhm Cardiovascular Institute at Northwestern Memorial Hospital in Chicago, IL, and one of the world's pre-eminent heart surgeons, will serve as Chairman of the Scientific Advisory Board. In addition, twelve other prominent cardiothoracic surgeons with extensive experience and expertise in the treatment of atrial fibrillation have accepted positions on the Scientific Advisory Board. This international and well-versed group of advisors will provide management with pivotal scientific guidance and will assist in establishing MedicalCV's current and future research and development activities. The Scientific Advisory Board will also provide clinical direction to support the acceleration of MedicalCV's clinical procedures and marketing efforts. These advisors bring impressive credentials in the cardiac field that support and validate MedicalCV's strategic focus. Combined, this group of advisors has well over one hundred years of experience in the cardiovascular / heart space and patient care. Chairman of the Scientific Advisory Board: -- Patrick M. McCarthy, MD Chief of Cardiothoracic Surgery and Co-Director of the Bluhm Cardiovascular Institute at Northwestern Memorial Hospital in Chicago, IL Members of the Scientific Advisory Board: -- Baron L. Hamman, MD Cardiothoracic Surgeon at Heart Place at Baylor University Medical Center in Dallas, TX -- Michael P. Caskey, MD Cardiothoracic Surgeon at Southwest Heart & Lung in Phoenix, AZ -- Marc Gerdisch, M.D. Cardiothoracic Surgeon at Cardiac Surgery Associates in Winfield, IL -- Lishan Aklog, MD Cardiothoracic Surgeon at Mount Sinai Medical Center in New York, NY -- Sudhir Srivastava, MD Cardiothoracic Surgeon at Cardiac Surgical Associates of West Texas in Odessa, TX -- Carmelo Otero, MD Cardiothoracic Surgeon at Cirujanos de Corazon Associates at Baptist Medical Center in San Antonio, TX -- Lonnie Whiddon, MD Cardiothoracic Surgeon at Texas Cardiothoracic Surgery Associates in Dallas, TX -- J. Michael Smith, MD Cardiothoracic Surgeon at Good Samaritan Hospital in Cincinnati, OH -- Robert R. Lazzara, MD Cardiothoracic Surgeon at Cardiac Surgical Associates in Tampa, FL -- Yousuf Mahomed, MD Cardiothoracic Surgeon at Indiana University School of Medicine, Clarian Cardiovascular Center in Indianapolis, IN -- Rainer G. Moosdorf, MD Professor and Director, Cardiac and Thoracic, Vessel Surgery at Phillips University of Marburg Hospital in Marburg, Germany -- Robert Svenson, MD Director of Electrophysiology, Central New York Cardiology in Utica, NY Commenting on the new Scientific Advisory Board, Marc P. Flores, President and Chief Executive Officer of MedicalCV, said, "We are very pleased to have such a distinguished group of surgeons with a wealth of experience, outstanding achievements and vast industry relationships, join our Scientific Advisory Board to help guide the research and development efforts of MedicalCV. End user input is essential at this point of development. All of these high caliber individuals are proficient in various treatments for atrial fibrillation, and are familiar with all of the technologies and energy sources available on the market today. We believe this board's input and experience will assist us in creating the stand-alone, minimally invasive (closed chest, beating heart) treatment for atrial fibrillation which is being designed with our laser platform of technology to mirror the positive outcomes associated with the gold standard Cox-Maze surgical procedure." He continued, "These advisors are all very active in the cardiac field, and are all well-regarded physicians. This renowned advisory board is validation to our products, concepts and the highly focused efforts of MedicalCV's management team. All of these physicians have a strong interest in the treatment of atrial fibrillation, which is a market that is projected to grow to $1.5 billion worldwide by 2008," Mr. Flores concluded. Dr. Patrick M. McCarthy, Chairman of MedicalCV's Scientific Advisory Board, said, "It is an honor to be a part of something as exciting as what MedicalCV is working on. The disease of atrial fibrillation is significant and prevalent worldwide. MedicalCV's laser-based technology offers momentous promise for the future treatment of atrial fibrillation in an elegant and minimally invasive fashion. The advisory board will be working closely with the management team to advance the ATRILAZE(TM) system's research and development, acceptance and utilization by cardiac surgeons into their practice, as an ideal and preferred treatment option for patients with atrial fibrillation." About MedicalCV, Inc. MedicalCV, Inc., a cardiovascular surgery device manufacturer, focuses on the development and introduction of products designed to improve patient outcomes through the early treatment of cardiovascular disorders and disease specifically, products used by cardiac surgeons to ablate cardiac tissue as a potential means to treat atrial fibrillation. The Company's core technology is the ATRILAZE(TM) Surgical Ablation System for use in cardiac tissue ablation procedures in open-heart surgery. The Company acquired this technology in August 2003 and received its FDA 510(k) clearance in November 2004. The ATRILAZE(TM) system is now available commercially for concomitant open-heart surgical procedures. The Company's common stock is traded on the OTC Bulletin Board under the symbol "MDCV." For further information on MedicalCV, Inc., please visit http://www.medcvinc.com/ . You may register to receive MedicalCV's future press releases and to be added to the Company's distribution list by visiting: http://www.roiny.com/form.php . This release contains certain forward-looking statements of expected future developments, as defined in the Private Securities Litigation Reform Act of 1995. The forward-looking statements in this release refer to our expectations regarding our development of products for the minimally invasive treatment of atrial fibrillation, and the potential size of markets for such products. These forward-looking statements reflect management's expectations and are based on currently available data; however, actual results are subject to future risks and uncertainties, which could materially affect actual performance. Risks and uncertainties that could affect such performance include, but are not limited to, the following: the Company's ability to fund significant capital needs; market acceptance in the U.S. of the Company's cardiovascular products; acceptance of minimally invasive techniques for the reduction of atrial fibrillation through ablation; potential reductions in pricing by competitors; the costs of licensing and acquiring new products and technologies; the time and costs involved in obtaining regulatory clearance for cardiovascular products; competing technological and market developments; physician acceptance of the Company's cardiovascular products; dependence upon governmental reimbursements and third party supplies; and the strength of the market for cardiovascular products. For more detailed information about these risks and uncertainties, please review the Company's current report on Form 8-K filed with the Securities and Exchange Commission on May 17, 2005. These events and uncertainties are difficult or impossible to predict accurately and many are beyond the Company's control. The Company assumes no obligation to publicly release the results of any revisions that may be made to any forward-looking statements to reflect events or uncertainties after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. The Company cites estimates of third parties as to the potential size of markets for its products; however, there can be no assurance such estimates will prove accurate. MedicalCV, Inc. Contact: Investor Relations Contact: John H. Jungbauer ROI Group Associates Vice President, Finance & CFO Robert Giordano Phone 651.452.3000 President Phone 212.495.0200, ext. 10 http://www.medcvinc.com/ DATASOURCE: MedicalCV, Inc. CONTACT: John H. Jungbauer, Vice President, Finance & CFO of MedicalCV, Inc., +1-651-452-3000, or ; or Investor Relations, Robert Giordano, President of ROI Group Associates, +1-212-495-0200, ext. 10, or Web site: http://www.medcvinc.com/ http://www.roiny.com/form.php

Copyright